Immediate Bisphosphonate Use With Endocrine Therapy Reduced Recurrence And Increased

[News]

The addition of zoledronic acid to adjuvant endocrine therapy increased bone mineral density and reduced the risk for disease recurrence among postmenopausal women with early hormone receptor-positive breast cancer, according to new data from the ZO-FAST trial. Richard de Boer, M.D...

More... (http://www.medicalnewstoday.com/releases/238826.php)